Semaglutide is a new generation of GLP-1 (Glucagon-like peptide-1) analog developed by Novo Nordisk Nordisk of Denmark. Its Molecular formula is C187H291N45O59, and its molecular weight is 4113.58. Semaglutide is based on the basic structure of Liraglutide and optimized on the basis of Liraglutide structure: it is obtained by changing alanine and lysine at positions 8 and 26 of Liraglutide to 2-amino Isobutyric acid and arginine, adding spacer (PEG chain) and acylating with stearic acid. This structure not only enhances the efficacy of Semaglutide, but also prolongs its half-life.